Integrative Analysis of Circulating Tumor DNA and Digital Pathology Score for Postoperative Risk Assessment in Colorectal Cancer

Integrative Analysis of Circulating Tumor DNA and Digital Pathology Score for Postoperative Risk Assessment in Colorectal Cancer - Histotyping in MONSTAR-3

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058699

Enrollment

200

Registered

2025-08-05

Start date

2025-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant solid tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Colorectal cancer patients undergoing radical surgical treatment enrolled in the MONSTAR-SCREEN-3 study (cohort B) who have not withdrawn consent or refused secondary use of their samples and information.

Exclusion criteria

Exclusion criteria: Data required for this study are missing. Cases for which the principal investigator determines that enrollment in this study is inappropriate.

Design outcomes

Primary

Measure	Time frame
Time-to-recurrence (TTR) in prognostic models using ctDNA and Histotyping. Diagnostic concordance for lymph node metastasis in prediction models using ctDNA and Histotyping.	—

Secondary

Measure	Time frame
Association between ctDNA, Histotyping score and efficacy of adjuvant therapy. Correlation between Histotyping and clinical outcomes including disease-free survival (DFS), overall survival (OS), and ctDNA positivity, as well as their associations with other clinicopathological and molecular biological features and perioperative treatments	—

Countries

Japan,Europe

Contacts

Public ContactTadayoshi Hashimoto

National Cancer Center Hospital East Department for the Promotion of Drug and Diagnostic Development

tadhashi@east.ncc.go.jp04-7133-1111

Outcome results